Rituximab for Anti-cytokine Autoantibody-Associated Diseases | MicrobiomeTrials← Back to trialsNCT01842386
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2014-04-29Est. Completion: 2021-05-06
Enrollment target: 7 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Pulmonary Alveolar Proteinosis (PAP)MARSGenetic Mutation
Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic form of alveolar proteinosis…
Paris, FranceCompleted Nov 6, 2021
Pulmonary Alveolar Proteinosis
The major goal of Part A of this study is to establish a National PAP Registry to help make reliable new research tests …
Cincinnati, United StatesEst. completion Dec 2030